Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E16.21 EPS (ttm)5.68 Insider Own0.01% Shs Outstand2.77B Perf Week1.50%
Market Cap255.01B Forward P/E14.39 EPS next Y6.40 Insider Trans-51.80% Shs Float2.77B Perf Month-7.22%
Income16.11B PEG3.35 EPS next Q1.45 Inst Own67.10% Short Float1.12% Perf Quarter-7.29%
Sales71.88B P/S3.55 EPS this Y18.50% Inst Trans-0.48% Short Ratio3.91 Perf Half Y-8.05%
Book/sh25.66 P/B3.59 EPS next Y3.78% ROA12.30% Target Price109.66 Perf Year-8.34%
Cash/sh12.26 P/C7.51 EPS next 5Y4.84% ROE22.60% 52W Range81.79 - 106.63 Perf YTD-9.99%
Dividend3.00 P/FCF45.63 EPS past 5Y5.30% ROI18.40% 52W High-13.64% Beta0.64
Dividend %3.26% Quick Ratio2.20 Sales past 5Y3.70% Gross Margin69.50% 52W Low12.59% ATR2.39
Employees126500 Current Ratio2.50 Sales Q/Q-52.70% Oper. Margin28.30% RSI (14)36.50 Volatility2.31% 2.40%
OptionableYes Debt/Eq0.27 EPS Q/Q-49.10% Profit Margin22.40% Rel Volume1.84 Prev Close93.98
ShortableYes LT Debt/Eq0.20 EarningsJul 14 BMO Payout49.40% Avg Volume7.95M Price92.09
Recom2.50 SMA20-5.07% SMA50-6.02% SMA200-7.80% Volume14,588,756 Change-2.01%
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Sep-01-15 01:40PM  3 ways Tampa Bay can capitalize on the Johnson & Johnson deal at
Aug-31-15 05:02PM  A Word of Advice for Amgen: Objects in the Mirror Are Closer Than They Appear at Motley Fool
01:20PM  5 High-Yielding Strong Dividend Growth Stocks for the Long Haul
09:30AM  The Zacks Analyst Blog Highlights: 3M Company, General Electric, Intel and Johnson & Johnson
Aug-29-15 01:51PM  Janssen Pharmaceuticals Accused of Hiding Risperdal's Breast Effects In Boys at Forbes
Aug-28-15 04:01PM  The 4 Stocks That Held Down the DJIA on Friday at 24/7 Wall St.
01:31PM  Stocks near session lows
12:16PM  How Harry Styles may have hurt SeaWorld at MarketWatch
11:04AM  Dow 30 Stock Roundup: 3M Lowers 2015 Earnings Outlook, JNJ Subsidiary Sells Splenda
08:43AM  6 Solid Reasons You Should Invest in U.S. Stocks Now at TheStreet
07:47AM  More Bargain Hunting: Three Places to Find the Fattest Dividends at Forbes
Aug-27-15 07:29PM  Contact lens makers take fight over price law to court
05:28PM  Johnson & Johnson to Participate in the 2015 Wells Fargo 10th Annual Healthcare Conference PR Newswire
05:15PM  Contact lens makers taking fight over price law to court
03:35PM  Johnson & Johnson partners with PCH to help health care startups at
03:05PM  Bristol-Myers Squibb's success in Tampa was a major draw for Johnson & Johnson at
12:14PM  Johnson & Johnson goes to Silicon Valley with new hardware partnership at Fortune
12:04PM  Tampa wins Johnson & Johnson shared services North American HQ at
10:46AM  Things could get pricey if you wear contacts
09:17AM  Johnson & Johnson Earnings Q2, 2015
08:00AM  Contact lens makers see their day in court
Aug-26-15 05:05PM  J&J to Sell Sugar Substitute Splenda to Heartland Food
01:23PM  The 10 Most Recession-Proof Dividend Aristocrats at Insider Monkey
11:07AM  2Q15 Performance of AstraZenecas ING Segment
06:00AM  JNJ sheds Splenda in sweet deal
12:20AM  Splenda Sweetener Getting a New Owner at The Wall Street Journal
Aug-25-15 07:00PM  Lightning Round: This sector is toxic right now at CNBC
06:51PM  J&J Sells Splenda Sweetener at The Wall Street Journal
05:33PM  J&J sells popular Splenda sugar substitute to Heartland Food
03:03PM  Johnson & Johnson (JNJ) Stock Up on Splenda Sale at TheStreet
01:50PM  Johnson & Johnson Will Sell Splenda Sweetener to Heartland Food at Bloomberg
01:36PM  Heartland Food to buy J&J sweetener Splenda
12:50PM  Explaining the drop
12:39PM  4 Biggest Boomerang Stocks After Black Monday at TheStreet
06:40AM  7 Dividend Myths That Are Just Plain Wrong at Motley Fool
Aug-24-15 07:26PM  Pisani: Stocks' dramatic slide hits ETFs at CNBC
05:59PM  Scientists just made an important step toward a revolutionary flu shot you would only have to get once in your life
12:08PM  These High-Quality Stocks Just Got a Whole Lot Cheaper at Motley Fool
11:29AM  Scientists make breakthrough in search for universal flu vaccine at Financial Times
10:48AM  J&J's Diversified Strategy Is Working: Cowen at
Aug-21-15 05:23PM  Buy these stocks now
05:00PM  4 stocks to buy in today's selloff
Aug-20-15 12:53PM  The 2013 Merck-Pfizer Diabetes Deal Now Looks Very Savvy at Forbes
10:02AM  Dow slips triple digits, Nasdaq off 1% as growth concerns weigh at CNBC
Aug-19-15 10:18AM  8 Things You Probably Don't Know About Johnson & Johnson at Motley Fool
08:48AM  13F Recap: The Most Popular (And Unpopular) Stocks Of Q2
08:02AM  If You're in Your 60s, Consider Buying These 5 Stocks at Motley Fool
Aug-18-15 06:05PM  Patent Reform Should Not Bail Out Big Drug Companies at Forbes
04:09PM  Should Investors Worry about a Rate Hike in the US?
11:21AM  3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever at Motley Fool
10:33AM  Wait, There are Still Cheap Pharma Stocks? at
Aug-17-15 11:18AM  Billionaire Glenn Russell Dubins Top Picks at Insider Monkey
Aug-16-15 01:18PM  3 Charts That Show Healthcare Stocks Should Stay Hot for Years to Come at Motley Fool
Aug-14-15 10:06AM  Pfizers Revenue Falls by 7% in 2Q15
Aug-13-15 04:13PM  AQXP Takes Investors on Rollercoaster Ride
10:45AM  3 Numbers Every Dividend Investor Should Understand
10:04AM  The Chemical Works of Gedeon Richter Plc Earnings Q2*, 2015
09:35AM  Theravance, Inc. Earnings Q2*, 2015
Aug-12-15 05:03PM  Pfizer Stock Is Like An Extended Release Drug at Investopedia
02:35PM  America, like Coke, sweetens on Stevia at MarketWatch
01:35PM  Johnson & Johnson Cashes Out Of Aquinox Pharmaceuticals' Parabolic Rally
10:26AM  The 3 Most Important Metrics for Dividend Investors at Motley Fool
09:19AM  UK watchdog requires Reckitt to license K-Y brand for 8 yrs Reuters
07:13AM  Reckitt given UK go-ahead for K-Y merger at Financial Times
05:37AM  Reckitt Benckiser Gets U.K. Approval to Buy K-Y Lubricants at The Wall Street Journal
Aug-11-15 10:59AM  Johnson & Johnson Offers High Returns and Stability for a Bargain at TheStreet
Aug-10-15 06:31PM  Tweedy Browne Reduces 33 Stakes in Portfolio
06:12PM  Smart Beta ETFs: Is Yours Silly Or Seriously Good? at Investor's Business Daily
12:25PM  St. Jude Medical, Inc. Earnings Q2*, 2015
08:01AM  5 Things Johnson & Johnson Wants You to Know at Motley Fool
Aug-07-15 01:56PM  J&J gets partial win against Covidien in surgical patent case
10:30AM  Johnson & Johnson gets partial win in patent appeal against Covidien
01:26AM  PRESS DIGEST- New York Times business news - Aug 7
Aug-06-15 03:03PM  Johnson & Johnson (JNJ): 53 Years of Low Risk Dividend Growth at Insider Monkey
01:04PM  JOHNSON & JOHNSON Financials
12:34PM  IBM Promises To Read Your X-Rays With $1 Billion Deal. Can It Really Do That? at Forbes
09:45AM  Geron Q2 Loss Narrower-than-Expected, Imetelstat in Focus - Analyst Blog
08:33AM  Amgen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-05-15 05:37PM  CVS strips Viagra, other top drugs, from insurance coverage
10:41AM  Better Dividend Stock: Johnson & Johnson vs. Pfizer Inc. at Motley Fool
09:12AM  4 Pharmaceutical Stocks to Buy in Wake of Shire-Baxalta Bid at TheStreet
Aug-04-15 03:04PM  Bard Said to Pay $200 Million to Settle Vaginal Mesh Cases at Bloomberg
01:14PM  The Revenue Recession
11:29AM  3 MedTech Stocks to Buy Before Their Q2 Earnings - Earnings ESP
11:15AM  5 U.S. Mega Caps With Less Than 0.1% Insider Ownership
09:00AM  Take Calculated Risks to Profit From These 5 Dividend Stocks
07:58AM  Gilead Sciences, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-03-15 08:09PM  10-Q for Johnson & Johnson at Company Spotlight
03:01PM  Teva Announces Its Acquisition of Allergan Generics
Aug-02-15 08:00AM  5 Dividend Stocks for Your Portfolio at 24/7 Wall St.
Jul-31-15 04:32PM  JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report
04:24PM  Ebola game changer?
01:00PM  A game changer for Ebola cure
09:57AM  PerkinElmer Beats Q2 Earnings and Revenues; Guides Up - Analyst Blog
09:23AM  Revisiting Harry Potter Stocks on His 35th Birthday - Analyst Blog
Jul-30-15 05:35PM  Brilinta? Brintellix? FDA warns of drug name mix-ups
02:45PM  MedTech Industry Stock Outlook - July/Aug 2015 - Zacks Analyst Interviews
02:45PM  MedTech Industry Stock Outlook - July/Aug 2015 - Industry Outlook
08:56AM  Kimberly-Clark Corp. Earnings Analysis: By the Numbers
08:07AM  The Best Deals in Low-Risk Stocks at Motley Fool
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM
PRINCE CHARLESDirectorJun 02Buy99.222,500248,05023,145Jun 03 05:20 PM
Stoffels PaulusChief Scientific OfficerApr 28Option Exercise64.43228,68314,733,404281,723Apr 30 04:56 PM
Stoffels PaulusChief Scientific OfficerApr 28Sale100.73187,25018,862,14294,473Apr 30 04:56 PM
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM